News: Combination cuts AKI risk following septic shock procedure, study finds
Adding dobutamine to norepinephrine during surgical source control for septic shock reduced seven-day postoperative acute kidney injury (AKI) incidence by 36% compared with norepinephrine alone, a recent trial published in JAMA Network found.
New-onset or worsening AKI within seven postoperative days occurred in 22.8% of those who received dobutamine plus norepinephrine compared with 34.7% of those who received norepinephrine alone, researchers wrote.
Patients in the combination group had significantly lower median Sequential Organ Failure Assessment (SOFA) scores on postoperative day one compared with the norepinephrine-alone group (five versus six, respectively) and higher median urine output one hour after starting the intervention. No statistically significant differences were observed across nine other secondary outcomes, according to findings.
No specific intraoperative therapy has been established to counteract the combined insult, researchers noted, emphasizing that AKI “contributes substantially to morbidity and mortality.”
Incidence of AKI within seven days of surgery was the primary outcome. Secondary outcomes included SOFA scores on postoperative days one, three, and seven; mortality at 28 and 90 days; the percentage of patients requiring KRT within seven days; postoperative intensive care and hospital length of stay; and postoperative mechanical ventilation duration. Gastrointestinal perforation was the predominant indication for surgery (41.8%), followed by gastrointestinal obstruction (29.6%).
Postoperative AKI criteria were met via serum creatinine alone in 17.1% of all participants, urine output alone in 3.8%, and both criteria in 7.9%. In post hoc analyses, the incidence of stage 2 and 3 AKI was lower in the dobutamine plus norepinephrine group compared with the norepinephrine-alone group (stage 2: 4.8% versus 9.9%; stage 3: 7.9% versus 13.6%). There was no difference in stage 1 AKI between the groups (10.0% versus 11.2%).
New-onset AKI occurred in 17.9% of the combination group and 28.6% of the norepinephrine group.
Norepinephrine is a potent vasoconstrictor and can decrease regional renal blood flow, potentially increasing AKI risk.
The role of dobutamine in septic AKI prevention “has remained controversial,” the researchers noted. While dobutamine can increase renal blood flow and glomerular filtration rate, some prior observational studies suggested an association with greater AKI progression or need for kidney replacement therapy (KRT). The researchers also noted that these data suggest an opportunity to explore dobutamine treatment response heterogeneity across different clinical subtypes.
“Timely source control with surgical intervention is a cornerstone of management in septic shock, necessary in 20% to 30% of patients, and associated with improved outcome,” the authors noted. However, “hemodynamic instability in septic shock and surgical stress may compromise tissue perfusion and contribute to the development of AKI, despite intravenous fluids and vasopressor administration.”
Editor’s note: To read the full study, click here. To read additional coverage from MedPage Today, click here.
